SCHEMBL1484406

SCHEMBL1484406

C[C@]12CC[C@H](OC(=O)CCCCCCC(=O)O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP1A1 P05023 14/20 0.65
ATP1B1 P05026 14/20 0.65
ATP1A3 P13637 14/20 0.65
ATP1B2 P14415 14/20 0.65
ATP1A2 P50993 14/20 0.65
ATP1B3 P54709 14/20 0.65
FXYD2 P54710 14/20 0.65
ATP1A4 Q13733 14/20 0.65
TP53 P04637 4/20 0.65
LMNA P02545 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
PAX8 Q06710 2/20 0.65
NPC1 O15118 2/20 0.65
RAB9A P51151 2/20 0.65
CYP3A4 P08684 1/20 0.65
TSHR P16473 1/20 0.65
HIF1A Q16665 1/20 0.65
ATP12A P54707 1/20 0.65
HBB P68871 1/20 0.60
USP2 O75604 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24012131 0.94 ATP1A1 (0.65) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL11893748 0.89 ATP1A1 (0.62) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL13762512 0.89 ATP1A1 (0.69) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL1483335 0.87 TP53 (0.74) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL12370059 0.87 TP53 (0.74) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL26042802 0.87 TP53 (0.74) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL1483332 0.87 TP53 (0.74) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL21578398 0.87 TP53 (0.74) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL21681745 0.87 TP53 (0.74) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2
SCHEMBL1484407 0.86 TP53 (0.52) ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110076278-A1 Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders BIONAUT PHARMACEUTICALS INC 2011-03-31 US claimed
EP-1928470-A2 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS Bionaut Pharmaceuticals (US) 2008-06-11 EP claimed
WO-2007016656-A2 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS BTG INTERNATIONAL LIMITED (GB) 2007-02-08 WO claimed
US-20110076278-A1 Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders BIONAUT PHARMACEUTICALS INC 2011-03-31 US disclosed
EP-1928470-A2 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS Bionaut Pharmaceuticals (US) 2008-06-11 EP disclosed
WO-2007016656-A2 MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS BTG INTERNATIONAL LIMITED (GB) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110076278-A1 Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders HIF1A, HIF1AN, HYOU1 ATP1A1 307/4885ATP1B1 102/4885ATP1A3 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.